Skip to content

About Us
Inobrodib
News
- Press Releases
- Publications
Contact Us

About Us
Inobrodib
News
- Press Releases
- Publications
Contact Us

ASCO, Chicago (2017)

Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of CRPC

Applications

Inobrodib is currently being evaluated for safety and efficacy in different multiple myeloma patient populations

Multiple Myeloma

Multiple myeloma (MM) and other hematological malignancies are regulated in part by p300/CBP.

Other Potential Applications

Inobrodib may have therapeutic utility in other p300/CBP-regulated cancers including acute myeloid leukemia (AML), lymphomas, solid tumors and targeted tumors with specific genetic mutations.

About CellCentric

CellCentric is a clinical-stage biopharmaceutical company focused on the development of a first-in-class oral p300/CBP inhibitor to treat multiple myeloma and other cancer types.

Quick Links

About Us
Inobrodib
Clinical Trials
Publications
Our Story

About Us
Inobrodib
Clinical Trials
Publications
Our Story

Our Team
News
Contact
Expanded Access Policy
Privacy Policy
Careers

Our Team
News
Contact
Expanded Access Policy
Privacy Policy
Careers

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Icon-x Linkedin-in

© CellCentric Limited 2026 | Company #4948632

Main Menu

About Us
Inobrodib
News
- Press Releases
- Publications
Contact Us

Follow us on LinkedIn